G. Targher

Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.

Cardiovascular-kidney-metabolic syndrome and the risk of liver-related and cardiovascular events across the steatotic liver disease spectrum.

A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.

Association between visceral adiposity index and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes mellitus: an exploratory cross-sectional study.

Higher VAI values are associated with MASLD in patients with T1DM, however, waist circumference outperforms VAI in identifying MASLD, suggesting that VAI may serve as a complementary marker of metabolic dysfunction rather than a standalone screening tool for MASLD in this patient population.

Trajectory of liver-related events following incident cardiovascular disease in MASLD: A 15-year population-based cohort study.

Individuals with MASLD who experience a CVD event have a higher subsequent risk of long-term LREs, and the value of targeted liver monitoring for high-risk individuals after CVD and integrated heart-liver co-management is underscored.